It is estimated that up to 10% of patients with high‐grade epithelial ovarian cancers have a pathogenic BRCA1/2 tumor mutation, yet their genomic instability scores are consistent with an HRD‐negative tumor [11, 28]. Here, BRCA1 is linked to neoplasm.